ATHERGENBIO Trademark

Trademark Overview

On Thursday, January 19, 2023, a trademark application was filed for ATHERGENBIO with the United States Patent and Trademark Office. The USPTO has given the ATHERGENBIO trademark a serial number of 97761230. The federal status of this trademark filing is NOTICE OF ALLOWANCE - ISSUED as of Tuesday, July 23, 2024. This trademark is owned by Athergen Inc.. The ATHERGENBIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Vaccine research and development; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines
athergenbio

General Information

Serial Number97761230
Word MarkATHERGENBIO
Filing DateThursday, January 19, 2023
Status688 - NOTICE OF ALLOWANCE - ISSUED
Status DateTuesday, July 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 28, 2024

Trademark Statements

Goods and ServicesVaccine research and development; Research and development of vaccines and medicines; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, February 9, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAthergen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDover, DE 19901
Party NameAthergen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDover, DE 19901

Trademark Events

Event DateEvent Description
Monday, January 23, 2023NEW APPLICATION ENTERED
Thursday, February 9, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, May 15, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, May 15, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 17, 2023ASSIGNED TO EXAMINER
Tuesday, October 24, 2023NON-FINAL ACTION WRITTEN
Monday, May 15, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, May 15, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, October 24, 2023NON-FINAL ACTION E-MAILED
Tuesday, October 24, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 24, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, January 24, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, January 26, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, January 26, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, April 22, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 22, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 24, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 8, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 28, 2024PUBLISHED FOR OPPOSITION
Tuesday, May 28, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 23, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, January 26, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, January 26, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 22, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE

Related Keywords

athergenbio research development vaccines fields immunopharmaceuticals services medicines vaccine engineering testing